Classification and Pathology of Lung Cancer

Area of Science:

• Oncology
• Pathology
• Molecular Diagnostics

Background:

• Lung tumor biology advancements necessitate updated classifications.
• The 2015 World Health Organization (WHO) classification represents a significant refinement in lung cancer diagnosis.
• Accurate classification is crucial for effective patient management and targeted therapies.

Purpose of the Study:

• To highlight the key changes and implications of the 2015 WHO classification of lung cancer.
• To emphasize the importance of distinguishing adenocarcinomas in small biopsies for molecular testing.
• To outline the prognostic significance of architectural patterns in adenocarcinoma resection specimens and the classification of neuroendocrine tumors.

Main Methods:

• Review and analysis of the 2015 WHO classification guidelines for lung cancer.
• Focus on diagnostic criteria for adenocarcinoma in small biopsies and resection specimens.
• Examination of features used to classify neuroendocrine tumors, including proliferation rate.

Main Results:

• The 2015 WHO classification provides refined criteria for lung cancer diagnosis.
• Distinguishing adenocarcinomas is critical for selecting patients for targeted molecular testing.
• Adenocarcinomas are further subclassified by architectural patterns in resections, offering prognostic information.
• Neuroendocrine tumors are categorized into typical carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma based on specific features.

Conclusions:

• The 2015 WHO classification improves the accuracy of lung cancer diagnosis and subtyping.
• Accurate classification facilitates personalized medicine approaches through targeted molecular testing.
• Understanding tumor biology and classification is essential for determining prognosis and guiding treatment strategies in lung cancer.